8-K: Arbutus Biopharma Reports Q4 and Year-End 2024 Financial Results, Announces Corporate Restructuring

Arbutus Biopharma announced its Q4 and year-end 2024 financial results, a corporate restructuring including a workforce reduction, and provided an update on its pipeline and litigation efforts.

Summary

• Arbutus Biopharma reported its financial results for the fourth quarter and year ended December 31, 2024.
• The company is undergoing a corporate restructuring, including a 57% workforce reduction and termination of its ATM program.
• Tuan Nguyen has been appointed as the new Chief Financial Officer, succeeding David C. Hastings.
• The company is reviewing its pipeline and development plans for its HBV programs, including imdusiran.
• Arbutus is continuing to pursue litigation related to its LNP technology against Moderna and Pfizer/BioNTech.
• The company's cash, cash equivalents, and investments totaled $122.6 million as of December 31, 2024.
• Total revenue for the year ended December 31, 2024, was $6.2 million, compared to $18.1 million in 2023.
• The net loss for the year ended December 31, 2024, was $69.9 million, or $0.38 per share.
• The company expects to incur a one-time restructuring charge of approximately $11 million to $13 million in the first quarter of 2025.
• The company expects to significantly reduce its net cash burn in 2025 when compared to 2024.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The strong cash position and potential for imdusiran are positives, but the restructuring and revenue decline are concerning.

Positives

• Arbutus has a strong financial position with $122.6 million in cash, cash equivalents, and investments as of December 31, 2024.
• The company expects to significantly reduce its net cash burn in 2025.
• The company is advancing imdusiran into a Phase 2b trial.
• Arbutus achieved a functional cure rate of 50% (3/6) in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL in the IM-PROVE I Phase 2a clinical trial.
• The company is actively defending its intellectual property through litigation.

Negatives

• The company is undergoing a significant restructuring, including a 57% workforce reduction.
• Total revenue decreased by $11.9 million year-over-year, primarily due to decreased revenue recognition from the Qilu collaboration and decreased license royalty revenues.
• The company reported a net loss of $69.9 million for the year ended December 31, 2024.
• The company is discontinuing in-house scientific research.

Risks

• The outcome of the Pfizer/BioNTech mRNA-LNP vaccine litigation is pending.
• The company's review of its pipeline and development plans for its cHBV programs may lead to changes in strategy.
• The workforce reduction and restructuring may negatively impact the company's operations.
• The company's cash resources may not be sufficient for its foreseeable and unforeseeable operating expenses and capital expenditures.

Future Outlook

Arbutus expects 2025 to be a transformative year and anticipates significantly reducing its net cash burn compared to 2024. The company will provide an update on its pipeline and development timeline upon completion of its review of its chronic hepatitis B virus (cHBV) programs.

Management Comments

• Lindsay Androski, President and CEO, stated she is excited to lead the company into its next chapter and is focused on evaluating strategies to accelerate the development and potential approval of imdusiran.
• Ms. Androski also welcomed Tuan Nguyen to the leadership team, reinforcing the company's renewed focus on advancing its pipeline efficiently and delivering value to patients and stakeholders.

Industry Context

Arbutus's focus on HBV and its LNP technology places it in a competitive landscape with other biopharmaceutical companies developing treatments and delivery systems for infectious diseases. The litigation against Moderna and Pfizer/BioNTech highlights the importance of intellectual property in the vaccine development space.

Comparison to Industry Standards

• The functional cure rate of 50% in HBeAg-negative patients in the IM-PROVE I Phase 2a trial is a notable result compared to existing treatments for HBV, but further data is needed to assess its long-term efficacy.
• Companies like Gilead Sciences and Vir Biotechnology are also pursuing HBV therapies, and their clinical trial results will be important to compare to Arbutus's data.
• The litigation against Moderna and Pfizer/BioNTech is similar to other intellectual property disputes in the pharmaceutical industry, such as those involving AbbVie's Humira and Amgen's Enbrel.

Management Changes

Legal Proceedings

• Arbutus is involved in ongoing lawsuits against Moderna and Pfizer/BioNTech related to its LNP technology.
• The claim construction hearing for the lawsuit against Pfizer/BioNTech occurred in December 2024, and the court's ruling is pending.
• The jury trial in the Moderna U.S. litigation is currently scheduled for September 2025.
• The Company, alongside Genevant Sciences, filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology across 30 countries.

Stakeholder Impact

• Shareholders will be impacted by the restructuring, potential changes in strategy, and the outcome of the litigation.
• Employees are affected by the workforce reduction.
• Patients may benefit from the continued development of imdusiran and other HBV therapies.
• Suppliers and creditors may be impacted by the company's cost-cutting measures.

Next Steps

• Complete the review of cHBV programs and provide an update on the pipeline and development timeline.
• Advance imdusiran into a Phase 2b clinical trial.
• Continue to support Genevant Sciences in protecting and defending intellectual property through ongoing lawsuits.
• Await the court's ruling on the claim construction in the Pfizer/BioNTech litigation.
• Prepare for the jury trial in the Moderna U.S. litigation scheduled for September 2025.

Key Dates

Keywords

Arbutus Biopharma, financial results, corporate update, HBV, imdusiran, LNP litigation, restructuring, Tuan Nguyen, Chief Financial Officer, workforce reduction